Nov. 19 – The Italian pharmaceutical group Recordati announced the acquisition of five product lines marketed in Russia: Alfavit, Qudesan, Vetoron, Focus and Carnitone. The value of the transaction is RUB 2.7 billion, of which 97% was paid at closing. The brands of products acquired, OTC drugs and dietary supplements, are well known in Russia. In particular, the line Alfavit has a leading position in the market, including a wide selection of vitamin and mineral supply.
Qudesan is based coenzyme Q10, an adjuvant of cardiac function, used for the prevention and treatment of chronic fatigue and metabolic dysfunction. Vetoron contains beta-carotene; Focus has a base of blueberry anthocyanin and lutein used in eye disease prevention; and Carnitone is a source of L-carnitine. Annual total sales of these products are approximately RUB 1.0 billion.
